Dr. Paba-Prada is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
603 N Flamingo Rd
Ste 151
Pembroke Pines, FL 33028Phone+1 954-265-4325Fax+1 954-436-4606
Education & Training
University of TennesseeFellowship, Hematology and Medical Oncology, 2007 - 2010
Pennsylvania Hospital of the University of Pennsylvania Health SystemResidency, Internal Medicine, 2004 - 2007
Industrial University of Santander Faculty of MedicineClass of 2000
Certifications & Licensure
FL State Medical License 2009 - 2026
MA State Medical License 2010 - 2022
TN State Medical License 2009 - 2010
PA State Medical License 2004 - 2007- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
Publications & Presentations
PubMed
- 53 citationsIncidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantationMathew Weinstock, Yosra Aljawai, Elizabeth A. Morgan, Jacob P. Laubach, Muriel Gannon
British Journal of Haematology. 2015-06-01 - 61 citationsMelflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study.Paul G. Richardson, Sara Bringhen, Peter M. Voorhees, Torben Plesner, Ulf-Henrik Mellqvist
The Lancet. Haematology. 2020-03-23 - 62 citationsPhase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myelomaEric K. Rowinsky, Agne Paner, Jesus G. Berdeja, Claudia E. Paba-Prada, Parameswaran Venugopal
Investigational New Drugs. 2020-03-03
Abstracts/Posters
- Updated Results of a Phase 2 Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVd-lite) in Transplant-Ineligible Multiple MyelomaClaudia E. Paba-Prada, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Results from Phase 1/2 Trial of Tagraxofusp in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple MyelomaClaudia E. Paba-Prada, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
